Skip to document

Increase in Drug Prices in America

One page introduction on the Increase in Drug Prices in America
Course

American Government (POLS 1101)

48 Documents
Students shared 48 documents in this course
Academic year: 2017/2018
Uploaded by:
0followers
41Uploads
6upvotes

Comments

Please sign in or register to post comments.

Preview text

Political Science 1101 Nathan Combes 24 February 2018 Increase in Drug Prices in America There has always been a huge problem with government regulation on life-saving drugs. According to the U. News, spending on prescription drugs have risen at a rate faster than any other health care cost. U. News also said that, “voters and candidates from both parties registered outrage at high drug prices.” In 2016, Hillary Clinton proposed to protect U. consumers from large increases in life saving drug prices. About 33% of voters agree with Clinton, because the lowering of drug price costs will shorten the lifespan of patients. Even Donald Trump has stated that the drug companies were “getting away with murder.” Other consumers say that if they don’t increase prices, less money will go into medical research to improve upon our current medicines. Most people who live healthy lifestyles may not realize how expensive the cost of medicine if they have insurance to cover costs and needs consumers who happen to be in a serious condition, might not even have insurance that will cover it all. It has been reported by AARP that within the next year, drug prices will increase by about 8% due to specialty medications. Due to the lack of strong competition among manufacturers of generic drugs, biologics, and biosimilars, there is less price competition and higher prices. Competition is restricted due to drug shortages and the removal of generic medications from the market. Brand-name manufacturers block potential competitors from obtaining drug samples needed to execute bioequivalence studies. I think we should rebalance price competition, prioritize patient access and affordability, and maximize the availability of

information to improve patient care. Works Cited AARP Bulletin May 2017|Comments: and AARP Bulletin May 2017. “Why Prescription Drugs Cost So Much.” AARP, 1 May 2017, aarp/health/drugs-supplements/info-2017/ rx-prescription-drug-pricing. Fielding, Jonathan. “The High Cost of Rising Drug Prices.” U. News, 21 Dec. 2017, usnews/opinion/policy-dose/articles/2017-12-21/the-high-cost-of-rising-drug- prices. Waxman, Henry, et al. “Getting to the Root of High Prescription Drug Prices.” The Commonwealth Fund, 10 July 2017, commonwealthfund/publications/issue- briefs/2017/jul/getting-to-root-high-prescription-drug-prices.

Was this document helpful?

Increase in Drug Prices in America

Course: American Government (POLS 1101)

48 Documents
Students shared 48 documents in this course
Was this document helpful?
Political Science 1101
Nathan Combes
24 February 2018
Increase in Drug Prices in America
There has always been a huge problem with government regulation on life-saving drugs.
According to the U.S. News, spending on prescription drugs have risen at a rate faster than any
other health care cost. U.S. News also said that, “voters and candidates from both parties
registered outrage at high drug prices.” In 2016, Hillary Clinton proposed to protect U.S.
consumers from large increases in life saving drug prices. About 33% of voters agree with
Clinton, because the lowering of drug price costs will shorten the lifespan of patients. Even
Donald Trump has stated that the drug companies were “getting away with murder.” Other
consumers say that if they don’t increase prices, less money will go into medical research to
improve upon our current medicines. Most people who live healthy lifestyles may not realize
how expensive the cost of medicine if they have insurance to cover costs and needs.Other
consumers who happen to be in a serious condition, might not even have insurance that will
cover it all.
It has been reported by AARP that within the next year, drug prices will increase by about
8% due to specialty medications. Due to the lack of strong competition among manufacturers of
generic drugs, biologics, and biosimilars, there is less price competition and higher prices.
Competition is restricted due to drug shortages and the removal of generic medications from the
market. Brand-name manufacturers block potential competitors from obtaining drug samples
needed to execute bioequivalence studies. I think we should rebalance price competition,
prioritize patient access and affordability, and maximize the availability of information to